GoldenGolden
Advanced Search
Neubase Therapeutics

Neubase Therapeutics

Neubase Therapeutics is a company founded in 2018 by Dietrich Stephan.

NeuBase Therapeutics, Inc., is a company that is accelerating the genetic revolution by developing a new class of designer synthetic medicines.

The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform enables rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people who are affected by genetic diseases, including people that can only be treated accessing of double-stranded DNA and RNA structures. NeuBase aims to address genetic neurological disorders using PATrOL™ technology,.

The Peptide-nucleic acid Antisense Oligo platform of NeuBase or PATrOL™ platform, uses sequences of engineered peptide-nucleic acids (PNAs), while PNAs of NeuBase are designed to bind mutant genes and inhibit them from manifesting into disease.

The PATrOL platform yields therapeutics with the broad tissue distribution that is the hallmark of small molecules, while maintaining the specific targeting that is characteristic of traditional genetic medicines.

NeuBase develops its PATrOL-enabled therapies using multiple types of nucleic acid bases, that include those that are engineered or natural, enabling increased selectivity and optimization of the therapy for the target disease. NeuBase is the first company to create bifacial Janus bases, engineered bases that target double-stranded DNA by engaging both strands at the same time.

NeuBase has developed a proprietary chemistry to decorate its candidates, which allows the therapies to be delivered systemically and achieve broad tissue distribution. It also possesses programs in place that enable more focused delivery to target tissues when they are advantage for maximizing efficacy.

NeuBase's chemists invented a method that gives its PATrOL-enabled drugs the advantages of small molecule therapies. These PATrOL-enabled drugs have proprietary “linkers” on each end, which allow cooperative binding across the gene target. This self-assembly capability confers the ability to address various mutational types such as large expansions and small single-base mutations.

Timeline

May 25, 2021
NeuBase Therapeutics announces the appointment of Kia Motesharei as Chief Business and Strategy Officer.

Funding rounds

Patents

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 25, 2021
BioSpace
Expansion of management team continues with addition of an industry leader with deep experience in business development, licensing, and strategy in the life-science industry
BioSpace
May 20, 2021
BioSpace
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced the appointment of Sandra Rojas-Caro, M.D., as Chief Medical Officer, effective May 24, 2021. With more than 20 years of drug development experience across all phases of drug development,
BioSpace
May 12, 2021
BioSpace
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the appointment of Gerald (Gerry) J. McDougall to the Company's Board of Directors
BioSpace
December 2, 2020
BioSpace
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the appointment of Curt Bradshaw, Ph.D., as its new Chief Scientific Officer.
Alex Keown
November 20, 2020
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.